CA1053108A - Osmotically driven fluid dispenser - Google Patents

Osmotically driven fluid dispenser

Info

Publication number
CA1053108A
CA1053108A CA261,892A CA261892A CA1053108A CA 1053108 A CA1053108 A CA 1053108A CA 261892 A CA261892 A CA 261892A CA 1053108 A CA1053108 A CA 1053108A
Authority
CA
Canada
Prior art keywords
bag
dispenser
fluid
exterior
plug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA261,892A
Other languages
French (fr)
Inventor
James B. Eckenhoff
Neil A. Johnson
Su I. Yum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of CA1053108A publication Critical patent/CA1053108A/en
Expired legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D63/00Apparatus in general for separation processes using semi-permeable membranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

PATENT APPLICATION OF ALZA CORPORATION
ALZA FILE NO.: ARC 491 TITLE: OSMOTICALLY DRIVEN FLUID DISPENSER

ABSTRACT OF THE DISCLOSURE

An osmotically driven fluid dispenser that is capable of being miniaturized and used as an implant to administer fluid drug compositions to animals and humans.
The dispenser comprises a flexible inner bag adapted to contain the drug composition, a fluid tight plug fitted into the bag opening, a port in the plug through which the composition may be charged to the bag, an intermediate layer of an osmotically effective solute composition partly cover-ing the bag exterior such that a band of the bag exterior proximate to the plugged end is not covered by the layer, an outer shape-retaining semipermeable membrane covering the layer of solute and forming a fluid tight seal at said band, and a tube that fits snugly through the port in the plug and extends substantially into the interior of the bag after the drug composition is charged to the bag, said tube providing an outlet through which the drug composition may be dispensed.

Description

I ARC ~191 ~ 3~

1 I BACKGI~OUN~ OF T~lE INVEI~TION
2 ~
1 The invention is an improvement in the osmotically
3 ¦ driven dispensers descrLbed in commonly owned Canadian S ¦ Patent No. 956~609.
1 The dispenser referred to therein as the "minipump" is espec-; 7 ¦ ially relevant. The minipump is an osmotically driven dispenser ¦ whose size makes it especially useful as a therapeutic system l for administering drugs to anirnals and humans. Its basic com-91 ponents are an inner flexible bag that holds the drug charge, 10 ¦ an intermediate layer of an osmotically effective solute com-121 position, such as an inorganic salt, that encapsulates the bag, ¦ an outer shape-retaining membrane that is permeable to water 131 and that encapsulates both the layer of osmotically effective 14¦ solute composition and the bag, and a filling/discharge port 151 that communicates with the interior of the bag.
16¦ In operation the bag is filled with drug via the 171 filling/discharge port and placed in an aqueous environment, ¦ such as a body cavity or within body tissue. Water is imbibed 19¦ from the environment by the osmotically effective solute through 20 1 the membrane into the space between the inner flexible bag and 21 ¦ the membrane. Since the bag is flexible and the membrane is 22 ¦ riyid, the imbibed water squeezes the bag inwardly thereby 24 ~ displacing drug out the filling/discharye port.

¦ I~r~C 491 ,,~

1 ~iinipumps of the above dcscribed structure and oper-2 ation perform well but are not beyond being improved. Two 3 shortcomings of those dispensers are, (1) they tend to lose
4 drug in bulk through the filling/discharge port, especially ~ when the dispenser is placed in an environment that experiences 6 significant movement, and (2) air bubbles trapped in the bag 7 during filling tend to completely or partially plug the filling/
8 discharge port. The former shortcoming affects the constancy 9 of the dosage rate adversely and may cause overdosing. The latter shortcoming may temporarily stop the dispensing or cause 11 the dosage rate to be erratic or unpredictable. The present 12 invention is directed towards eliminating or reducing both of 13 these shortcomings.

STATEMENT OF THE INVENTION
~6 17 The invention is an osmotically driven fluid d-ispenser ]8 comprising an elongated flexible inner bag closed at one end 19 and open at the other end and adapted to contain the fluid, a fluid tight plug fitted into the open end of the bag, a port 21 in the plug that provides a passageway from the interior of 22 the bag to the exterior of the dispenser through which the 23 fluid may be charged into the bag, an intermediate layer of 24 an osmotically effective solute composition covering the ex-terior of the bag, and an outer shape-retaining semipermeable .. . - - ~ : . ..

~nc .1 9 1 ¦

i3~
¦ membran~ covering the intermediate layer of osmotically effec-2 I tive solute composition, characterized in that- the osmotically 3 ¦ effective solute composition only partly covers the exter.ior 4 ¦ of the bag such that a band of the bag exter:ior proximate to : 5 ¦ the open end of the bag is not covered by the layer; the mem-61 brane forms a fluid tight seal with -the exterior of the bag at 7 ¦ said band; and the dispenser includes a conduit that fits snugly B ¦ through the port and extends into the interior of the bag after ~ 9 1 the fluid is charged to the bag, to provide an outlet through lO¦ which fluid may be dispensed from the bag under pressure.

: ,21 BRIEF DESCRIPTIOM OF T~]E DRAWINGS
: 131 : 14¦ In the drawings:
: 15¦ Figure l is an elevational, exploded, partly sectional 16¦ view of one embodiment of the dispenser of the invention;
~: 17¦ Figure 2 is an enlarged, sectional view of the dis-~ 18¦ penser of Figure l;
.~ 19¦ Figure 3 is an enlarged, elevational, partl~ sectional 20¦ view of another embodiment of the dispenser of the invention; an 21¦ Figure 4 is an enlarged, top plan view of the flow 22¦ moderator of the dispenser of Figure l~
: 231 Like numerals refers to like parts in the various : 241 flgures.
~ 251 '~ 261 ~7 ~81 3( ',, I . , , .., . .

~P~C ~91 ~ ~3g~8 I _E~AILED DE:scRIprrloN-oF Tl]E INVENTION

3 Figures 1 and 2 illustrate an osmotically driven 4 fluid dispenser, generally desiynated 11~ The basic components S of dispenser 11 are an outer, shape-retain.ing, sernipermeable 6 membrane 12, an intermed.iate layer 13 of an osootically effec-7 tive solute~ an inner flexible bag 14, a pluq 15, and a flow 8 moderator, generally designated 16.
g Bag 14 is adapted to contain a fluid composition, such as an active agent composition 17 (Fig. 2) in fluid form.
11 The term "active agent" as used herein means any compound or 12 mixture o: compounds that can be d.ispensed to produce a pre-13 determined beneficial and useful result. Active agents .include 14 pesticides, germicides, biocides, algicides, rodent.icides, fung.i-l~ cides, insecticides, antioxidants, plant growth promoters, plant 16 growth inhibitors, preservating agents, surfactants, disinfec-17 tants, sterilization agents~ catalysts, chemical reactants, 18 fermentation agents, cosmetics, foods, nutrients, food supple-19 ments, drugs, vitamins~ sex sterilants, fertility inhibitors, fertility promotors, air pur.if.iers, microorganism attenuators, 21 and other compos.itions that benefit the environment, surround-22 ings, and habitat .including ani.mals and humans~ In the pre-23 ferred embodiment the active agent is a drug that produces 24 a local or systemic phys.iological or pharmacological response when administered to animals or humans.
-5-~C 4~1 ~ (~53~
.
1 In order to bc a suitable container for the fluid, 2 the bag should be substantially impermeable to the composition 3 and be compatible with the compos:it;on. By "compatible", Lt 4 is meant that the bag should not be corroded, solubilized/ or S otherwise affected deleteriously by the composition. Addition-
6 ally, when the composition .is a drug or the like, the composi-
7 tion should not be sign.ificantly contaminated by the bag, such
8 as by the extraction of leachables from the material forming
9 the bag. Bag 14 may be made from elastomer.ic compositions that may be formed into thin sheets. The elastomeric proper-11 ties of the bag composition and the thickness of the bag wall l2 should be such as to permit the bag to readily collapse inwardly 13 when a force is applied to the bag exterior.
14 Bag 14 is elongated and generally cyl:indrical and is closed at its end 18 and open at its oppos.ite end 19. As seen .
16 in E'ig. 2, bag 14 is partly encapsulated by the layer 13 of ar.
17 osmotically effective solute composition such that a band 22 of the exterior of bag 14 proximate to open end 19 is not covered 19 by layer 13. The purpose of layer 13 is to imbibe water across membrane 12 into the space between the exterior of bag l4 and 21 the inner surface of membrane 12, that is, the space occup.ied 22 by layer 13. Osmotically effective solute compositions that 23 may be used to form layer 13 are disclosed in sa.id Canadian 24 Patent No. 956,609.

.

27 .

~ C ~91 ~ 3 1 ¦ L,ayer 13 is in turn encaps~lated by outer membrane 2 ¦ 12. ~embrane 12 also covers band 22 and forms a fluid tight 3 ¦ seal therewith. At least a part of membrane 12 is permeable 4 ¦ to water. Preferably all of membrane 12 is permeable to water~
5 ¦ Membrane 12 is impermeable to the osmotically ef~ective solute 6 ¦ composition~ Membrane 12 is also shape-retaining, that is, it 7 ¦ is sufficiently rigid to be substantially undeformed by the 81 hydrostatic pressure that is generated in the space between.its 9¦ inner surface and the exterior of bag 14 by the water imbibed
10¦ by layer 13, The th:ickness and composition of membeane 12
11¦ affect the rate at which water will be imbibed through it by ,21 layer 13.
13¦ Plug 15 fits into the open end 19 of bag 14. Plug 15 ~ 14¦ is generally cylindrical and is approximately as long as band ~ IS¦ 22. The exterior of plug 15 forms a fluid tight seal with . 61 the portion of the interior surface of bag 14 with which it .' i71 is in contact. Plug 14 has an axial, central bore 23 extending ,81 completely through it. Bore 23 provides access to the interior of bag 14 for filling bag 14 with composition 17. Bore 23 is also adapted to receive flow moderator 16. Plug 15 may be made 21 from the same materials as are used to make flexible bag 1~;
:. 22 however, the d.irnens.ions of plug 15 should be such that it is 23 substant:ially inflexible.
Flow moderator 16 provides the passageway from the interior of bag 14 to the exter.ior of dispenser 11 by which 2~ _7_ 33l ¦ ~RC ~9l ~0~3~8 1 composition 17 is dischaLged from dispenser ].1. Flow moderato~
2 lG comprises a conc~uit, in the form of a rigid cylindrical 3 tube 24, and a head or cap 25. Tube 24 and head 25 may be made from suitable plastics or metals, respectively. The outer diameter of tube 24 is approximately the same as the diameter of bore 23 such that tube 24 may be inserted through bore 23 7 into bag 1~ with tube 24 fitting snugly w;thin bore 23 so as . ~ to form an essentially fluid tight seal with pluy 15. The :- 9 length of tube 24 is such that it extends into bag 14 to at least about 50% of the elongated dimension of the interior 11 of bag 14, i.e., the distance from the inner side of end 18
12 to the inner end of plug 15. Preferably tube 24 extends into
13 bag 14 over substantially the entire, but not all of (say 85%
14 to 95%), of said elongated dimension~ The inner diameter of . - 15 tube 24 is correlated to the length of tube 24 such that sub-16 stantia~ d:iffusional flow of composition 17 through tube 24 17 will not occur. Tube 24 is, in effect, a capillary that pro-18 vides resistance to the flow of composition 17, thereby reducing 19 or eliminating bulk loss of composition 17 from the outlet port of dispenser 11. Althou~h not shown in the drawings, tube 24 ~ 21 may extend outwardly from the exter.ior of head 25 to provide 22 a site for attachment of a catheter or other dispensing means.
23 Head 25 ls hemispher.ical and has a diameter approximately equal 24 to the outer diameter of dispenser 11. It also has a diamet-: 25 r.ical bore 26 for receiving tube 24. As seen .in Fig. 2, the ` 27 ` 32 ! ~c ~91 I
I ¦ flat side o head 25 fits against the top of plug 15 and the 2 ¦ top edge of bag 14. Thus the spherical surface of head 25 3 ¦ provides a smooth blunt surface that generally alLgns with 4 ¦ the exterior surface of the bag-solute layer~membrane assembly, S ¦ which bluntness and alignment are important if the d.ispenser 6 ¦ is to be used as an implant to adm.inister drugs to an.imals or 7 ¦ humans. Referring to Fig. 4, head 25 has three radial, equi-8 ¦ spaced grooves 27 in its spherical surface that intersect at 9¦ bore 26. The outer end of tube 24 is inset sl;ghtly from the 10¦ spherical surface of head 25 (Fig. 2) and thus grooves 27 11¦ serve as flow channels for composition 17 exiting from the 12¦ outer end of tube 24.
13¦ Fig. 3 illustrates an osmotic dispenser, generally 14¦ designated 28 that is identical to dispenser 11 except in one ¦ respect, namely outer membrane 12 encapsulates the top edge of .
16¦ bag 14 and the top of plug 15 as well as the arcuate surfaces 17 of layer 13 and band 22. As discussed below, this difference 18 is caused by a difference in the techniques by which the mem-brane 12 is applied to dispensers 11 and 28. Like dispenser 11, dispenser 2~ also consists of an outer, shape-reta.in.ing, semi-21 permeable membrane 12, an intermed:iate layer 13 of an osmoticall~ , 22 effective solute, an inner flexible bag 14 adapted to contain a 23 fluid 17, a plug 15, and a flow moderator 16. These components 24 are of identical structure, composition, and interelationship as their like numbered counterparts of dispenser 11 except for 26 the single difference mentioned above.
27 .

_9_ 3l ~2 : . : : ~ . :

~J~C ~91 1 Th~ components of di~p~nser 11 may be made and 2 assemble~l as follows. Bag 14 may be injection molded from 3 suitable polymer compositions by known techniques. Bag 14 4 is then pla~ed on a support means, such as a mandrel, and a suspension of the osmotically effective solute in an appro-6 priate suspending medium is prepared~ The supported bag 14 7 is then dipped repeatedly in the suspension to the desired 8 depth, with intervening drying periods, until a layer 13 of 9 desired thickness is formed. A solution of membrane material is then made and the supported, solute coated bag 1~ is dipped 11 repeatedly into the solution to a depth just above the top 12 edge of bag 14, with intervening drying periods, until a mem 13 brane 12 of desired thickness is formed. The mandrel is then 14 removed and plug 15, which may be injection molded by known techniques, is glued into the open end o~ bag 14~ Head 25 16 may be machined by known techniques if it is metal, or injec-17 tion molded by known techniques if made from a synthetic poly-18 mer. The end of tube 24 may be affixed within bore 26 by 19 press-fittingr gluing, or other known techniques.
Dispenser 28 may be assembled as ollows~ A solute 21 coated bag 14 is made as in the case of dispenser 11. Plu~
22 15 is then fixed in place in the open end of bag 14 as in the case of dispenser 11. Membrane 12 of dispenser 28 is 24 then applied to the solute coated, plugged bag 14 by air s~spension-solution coating techn;ques in a Wurster coating 2~
3() -10-I ~C~lgl ;i3~

1 ¦ apparatus. Such apparatus and techniques are ~ell known.
2 ¦ This manner of ormin~ mernbrane 12 encapsulates the entire 3 ¦ bag-solute layer-plug assembly. Accordingly, a hole must 4 ¦ be formed through membrane 12 to bore 23 of plug 15. This S ¦ may be done by drilling, punching, or equivalent techniques.
6 ¦ Dispensers 11 and 2~ may be filled with fluid 17 7 I via bore 23 of plug 15. For instance, the needle of a fluid B¦ loaded syringe may be inserted through bore 23 and the syr-9¦ inge's contents discharged into bag 14~ To insure that a 10¦ predetermined fluid pumping rate is ach;eved, it is desirable 11¦ to completely fill bag 14 with fluid 17. After the bag is ,21 filled, tube 24 of flow moderator 16 is inserted through bore 13¦ 23 to the position shown in Figs. 2 and 3. As described 14 above tube 24 functions as a capillary and inhibits loss of fluid 17 from the dispensers even though they are subjected 16 to substantial movement or tipped upside down.
17 Dispensers 11 and 28 operate in the following manner.
l8 Once placed in an aqueous environment, such as within a body 19 cavity or within body tissue, water from the environment i5 imbibed by layer 13 through membrane 12 at a rate determined 21 by the osmotic activity of the osmotically efEective solute, 22 and the osmotic reflection coefficient, composition, thickness, 23 and area of membrane 12. The imbibed water causes the volume 24 of the space between the inner surface of membrane 12 and the 26 exterior of bag 14 (the space initially occupied by layer 13) 29 -11~

: -l to increase. And since membrane 12 is shape-retaining, the 2 im~ibed water generates hydraulic pressure on the exterior of 3 bag 14 causing bag 14 to be squeezed inwardly. This squeezing 4 forces fluid 17 through tube 24 and out of the dispenser. Any air bubbles that were trapped within bag 14 dur~ing filling 6 will tend to be located adjacent to the inner end of plug 15 7 or the inner surface of baq 14, depending on the attitude of 8 the dispenser. Therefore, these air bubbles are not likely 9 to block the entrance to tube 24 and interrupt or impede the flow of fluid 17 therethrough.
l1 As indicated, fluid 17 may be an active agent com-12 position. In such instances the dispensers 11 or 28 will, of 13 course, discharge active agent directly. Alternatively, fluid 14 17 may be inert and the dispenser may be used simply as a IS displacement pump. In this alternative the dispenser will, 16 of course, have to be suitably interconnected to a reservoir 17 of the fluid (active agent) to be discharged, such that the 18 inert fluid displaces the fluid from the reservoir in a pre-l9 determlned regimen to the desired administration site. Such alternatives are particularly attractive in instances in which 22 ~ the fluid t e discharged is lncompatible with ba9 14.

2~ -12-:

I\RC 491 ~05~

EXAMPLES
2 ___ .
The following examples are intended to further illus-4 trate the above described dispensers and their manufacture.
These examples are not intended to limit the invention in any 6 way. Unless indicated otherwise, percentages and parts are 7 by weight.

9 Example l Cylindrical flexible bags (2.33 cm long, 3.81 mm 11 inner diameter, and 4.67 mm outer diameter) were injection molded at 180~C, 77-84 kg/cm 2 from an elastomeric styrene-131 butadiene copolymer (sold under the trade designation, Kraton 14¦ 2104). A mandrel was inserted into each bag and mandrel sup-~51 ported bags were attached to a dipping platform.
16¦ A suspension of potassium sulfate particles in 17¦ dioxane-cellulose acetate solution (50 wt %) was prepared 18¦ and the mandrel supported bags were dipped into the suspen-191 sion to a depth of 1.8 cm 4 times for 1 min. per dip with 201 an intervening 15 min. room air drying period. This dipping 21¦ coated the bags with an approx;mately 0.3 mm thick coating 221 of the suspension.
231 A solution of cellulose acetate (sold under the 241 trade designation, Eastman E-398~10) in acetone (15 wt %) 251 was prepared and the mandrel-supported, potassium sulfate ,' 261 `12!71 . . .

- 31 . .
32 .
.~ , ,.... , . . ' ' :, . , ,:. ., . :

~ AI~C 431~

~ S3~

1 I coatcd bags werc dipp~cl completely in the svlution 20 times 2 ¦ for 1 min. per dip with an intervening 15 min. drying period.
3 ¦ Following this dipping the bags were oven dried at 60C for 4 1 15 days. This dipping formed a cellulose acetate mernbrane S ¦ approximately 0.65 mm thick about the entire bag exterior, ¦ including the potassium sulfate coated portion thereof.
7 I Cylindrical plugs of the above described styrene~
B¦ butadiene copolymer were injection moldedO The plugs were -9¦ 0.5 cm long, had a 3.9 mm outer diameter, and had a central axial bore 0.76 mm in diarneter. The arcuate surfaces of the 11¦ plugs were coated with a glue bead of a 20 wt % cyclohexane 121 solution of the copolymer and the plugs were inserted into 13¦ the open ends of the potassium sulfate-cellulose acetate coated 14¦ bags. A 22 gauge needle was ;nserted through the bore of each ~sl plug and the plugged bags were placed in an oven at 60C for 16¦ 2 hr.
17¦ Flow moderators were prepared for each dispenser as 18¦ follows Head or cap members were injection molded from styrene-191 acrylonitrile copolymer. The heads were generally hemispherical 20¦ 6.6 mm in diameter with a 0.8 mm diameter dlametrical bore. The 21¦ arcuate surface of the heads had three equispaced grooves that 22¦ intersected the bore. Twenty-one gauge needles were cut in 15 m~

231 lengths, blunted, inserted into the heads and glued in place 2~1 therein with an epoxy resin.
': 2sl .
: 26 ::' 27 :, ' ~ A~C 491 I ~S33L~D~

1¦ Example 2 21 Inner bags were made and coated with potassium sulfate 31 as described in Example 1. Plugs Eor the potassium sulfate 41 coated bags were made and glued into the open ends of the bags 51 as in Example 1. The potassium sulfate coated, plugged bags ¦ were then completely coated with a 0.65 mm thick membrane of 7¦ cellulose acetate in a small Wurster air suspension cGater. ?
81 (Air flow 15 m /min., air pressure 2 kg/cm 2 5 wt % acetone 9¦ solution of cellulose acetate, solution rate 50 ml/min., coat-~ol ing time 10 hr.) The bags were then oven dried at 60C for 11¦ 15 days and a hole was drilled in each membrane through to 12¦ plug bore. Flow moderators were made for each dispenser as 13¦ in Example 1.
14¦ The dispensers of Examples 1 and 2 were tested Ln ~51 vitro and in vivo by filling them with various fluids via I _ ~ _ 16¦ the plug bore, inserting the needle portion of the flow moder-17¦ ators through the plug bores down into the bags' interiors 18¦ and placing the dispensers in an appropriate environment.
19¦ In in vitro tests in water at 37C using FD ~ C Blue #l dye 201 in water as the fluid charge the dispensers dispensed the 21¦ solution at a flow rate of 1.7 x 10 3 ml/hr with ~ 1~3 x 10 4 22¦ ml/hr deviation. In in vivo tests using the same fluid charge 23¦ the dispensers were inserted subcutaneously into rats and pro-241 vided a flow rate of 1.0 x 10 ml/hr with ~ 8 x 10 ml/hr 25 ~ devlation.

,.: 271 .. ., . .
, . 281 . ' ' .

- 1,

Claims (8)

1. An osmotically driven fluid dispenser compris-ing an elongated flexible inner bag closed at one end and open at the other end and adapted to contain the fluid, a fluid tight plug fitted into the open end of the bag, a port in the plug that provides a passageway from the interior of the bag to the exterior of the dispenser through which the fluid may be charged into the bag, an intermediate layer of an osmotically effective solute composition covering the exterior of the bag, and an outer shape-retaining semipermeable membrane covering the intermediate layer of osmotically effective solute composition, characterized in that: the osmotically effective solute composition only partly covers the exterior of the bag such that a band of the bag exterior proximate to the open end of the bag is not covered by the layer; the membrane forms a fluid tight seal with the exterior of the bag at said band;
and the dispenser includes a conduit that fits snugly through the port and extends into the interior of the bag after the fluid is charged to the bag to provide an outlet through which fluid may be dispensed from the bag under pressure.
2. The dispenser as claimed in claim 1 characterized in that the conduit extends into the bag interior over at least about 50% of the elongated dimension thereof.
3. The dispenser as claimed in claim 1 characterized in that the conduit extends into the bag interior over substantially the entire, but not all of, elongated dimension thereof.
4. The dispenser as claimed in claim 1 characterized in that the conduit is rigid.
5. The dispenser as claimed in claim 1 characterized in that the length and inner diameter of the conduit are such as to prevent substantial diffusive flow of fluid therethrough.
6. The dispenser as claimed in claim 1 characterized in that the exterior end of the conduit terminates in a blunt head.
7. The dispenser as claimed in claim 6 characterized in that said head is shaped to fit snugly against the exterior of the dispenser and form a substantially smooth continuous surface therewith.
8. The dispenser as claimed in claim 6 characterized in that the head has at least one groove in its exterior surface that communicates with the bore of the conduit to provide a flow channel for the fluid.
CA261,892A 1975-10-01 1976-09-23 Osmotically driven fluid dispenser Expired CA1053108A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/618,492 US3987790A (en) 1975-10-01 1975-10-01 Osmotically driven fluid dispenser

Publications (1)

Publication Number Publication Date
CA1053108A true CA1053108A (en) 1979-04-24

Family

ID=24477937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA261,892A Expired CA1053108A (en) 1975-10-01 1976-09-23 Osmotically driven fluid dispenser

Country Status (12)

Country Link
US (1) US3987790A (en)
JP (1) JPS6039043B2 (en)
AU (1) AU499196B2 (en)
CA (1) CA1053108A (en)
CH (1) CH611800A5 (en)
DE (1) DE2644267A1 (en)
DK (1) DK156243C (en)
FR (1) FR2347059A1 (en)
GB (1) GB1517879A (en)
IL (1) IL50468A (en)
IT (1) IT1068729B (en)
SE (1) SE417158B (en)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
DE2626294C3 (en) * 1976-06-11 1980-01-10 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantable dosing device
DE2626348C3 (en) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantable dosing device
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4180073A (en) * 1977-08-29 1979-12-25 Alza Corporation Device for delivering drug to biological environment
US4223061A (en) * 1977-10-25 1980-09-16 Alza Corporation Hydrophilic laminate useful for making dispensing device
US4192308A (en) * 1977-10-25 1980-03-11 Alza Corporation Device using prestretched polymer for dispensing medication
US4304232A (en) * 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
DE2911558A1 (en) * 1979-03-23 1980-09-25 Alza Corp Liq. dispensing device - contains hydrophilic, water-insol. water-swellable polymer layer between compressible container and rigid casing
FR2452918A1 (en) * 1979-04-02 1980-10-31 Alza Corp Liq. dispensing device - contains hydrophilic, water-insol. water-swellable polymer layer between compressible container and rigid casing
GB2048710B (en) * 1979-05-07 1983-03-09 Alza Corp Osmotically driven fluid dispenser
US4320758A (en) * 1979-05-07 1982-03-23 Alza Corporation Osmotically driven fluid dispenser
US4237893A (en) * 1979-11-28 1980-12-09 Alza Corporation Cervical dilator
US4299222A (en) * 1980-01-08 1981-11-10 Alza Corporation Self-contained suction pump
US4300558A (en) * 1980-07-18 1981-11-17 Alza Corporation Self-driven fluid dispenser
US4455144A (en) * 1980-12-04 1984-06-19 Alza Corporation Dispenser constructed with semipermeable polymer-hydrophilic polymer wall
US4340048A (en) * 1981-03-28 1982-07-20 Alza Corporation Self-driven hypodermic injector
FR2513243B1 (en) * 1981-09-24 1983-11-18 Commissariat Energie Atomique
US4474575A (en) * 1982-02-01 1984-10-02 Alza Corporation Self-driven pump assembly and method of operation
US4539004A (en) * 1982-09-22 1985-09-03 Alza Corporation Self-driven pump assembly and method of operation
AU591171B2 (en) * 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4800056A (en) * 1984-03-21 1989-01-24 Alza Corporation Process for making dispenser with cooperating elements
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
JP2598258B2 (en) * 1987-01-30 1997-04-09 セイコー電子工業株式会社 Spatially resolved spectrometer
US4772287A (en) * 1987-08-20 1988-09-20 Cedar Surgical, Inc. Prosthetic disc and method of implanting
US4929233A (en) * 1988-08-26 1990-05-29 Alza Corporation Implantable fluid imbibing pump with improved closure
US4946456A (en) * 1988-08-26 1990-08-07 Alza Corp. Fluid imbibing pump activated by capillary action of a fabric or polymeric sleeve
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US4976966A (en) * 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US4969872A (en) * 1989-03-08 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5024663A (en) * 1990-02-21 1991-06-18 Alza Corporation Self-contained suction pump
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
DE4301782C1 (en) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Use of galanthamine to treat nicotine addiction
DE4313928C2 (en) * 1993-04-28 1996-09-19 Lohmann Therapie Syst Lts Transdermal therapeutic system for the controlled delivery of pilocarpine to the skin, process for its production and its use
WO1995001203A2 (en) * 1993-06-23 1995-01-12 Cytotherapeutics, Inc. Implantable membrane encapsulation apparatus
DE4342173A1 (en) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmaceutical formulation for the prophylaxis or pretreatment of poisoning by organophosphorus cholinesterase inhibitors
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
DE69734168T2 (en) * 1996-02-02 2006-01-19 Alza Corp., Mountain View Implantable system with delayed release of active ingredient
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
PT1066081E (en) 1996-11-15 2003-12-31 Alza Corp OSMOTIC DISTRIBUTION SYSTEM AND PROCESS FOR IMPROVING THE START AND PERFORMANCE OF OSMOTIC DISTRIBUTION SYSTEMS
ATE203157T1 (en) * 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US7890176B2 (en) * 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
DE19906979B4 (en) 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Use of deoxypeganine for the treatment of nicotine addiction
DE19906974C2 (en) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Use of deoxypeganine for the treatment of alcoholism
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
WO2002043800A2 (en) * 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
DE19923551A1 (en) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmaceutical preparation with the active ingredient diamorphine and its use in a method for treating opiate addiction
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6616652B1 (en) 2000-02-15 2003-09-09 Microsolutions, Inc. Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
US6582441B1 (en) 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6582418B1 (en) * 2000-06-01 2003-06-24 Medtronic, Inc. Drug pump with reinforcing grooves
US20050143789A1 (en) * 2001-01-30 2005-06-30 Whitehurst Todd K. Methods and systems for stimulating a peripheral nerve to treat chronic pain
US7493172B2 (en) * 2001-01-30 2009-02-17 Boston Scientific Neuromodulation Corp. Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US20060064140A1 (en) * 2001-01-30 2006-03-23 Whitehurst Todd K Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
EP1374855A1 (en) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medicinal solutions
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
CN100446809C (en) * 2001-11-14 2008-12-31 阿尔扎有限公司 Injectable depot composition
DE60239556D1 (en) 2001-11-14 2011-05-05 Durect Corp CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US6978174B2 (en) * 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7151961B1 (en) * 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (en) 2002-06-25 2005-03-09 Alza Corp SHORT-TERM DEPOSIT FORMULATIONS
DK1539101T3 (en) 2002-07-31 2009-04-27 Alza Corp Injectable, multi-modal polymeric compositions and applications thereof
CA2494342A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US7254449B2 (en) * 2002-07-31 2007-08-07 Advanced Bionics Corp Systems and methods for providing power to one or more implantable devices
CA2497867A1 (en) 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US20060009739A1 (en) * 2002-09-06 2006-01-12 Durect Corporation Implantable flow regulator with failsafe mode and reserve drug supply
ATE418323T1 (en) 2002-11-06 2009-01-15 Alza Corp DEPOSIT DELAYED RELEASE FORMULATIONS
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR20060017749A (en) * 2003-03-31 2006-02-27 알자 코포레이션 Osmotic pump with means for dissipating internal pressure
CN1767815A (en) * 2003-03-31 2006-05-03 阿尔萨公司 Non-aqueous single phase vehicles and formulations utilizing such vehicles
BRPI0408921A (en) * 2003-03-31 2006-03-28 Alza Corp osmotic distribution system and method for decreasing start times for osmotic distribution systems
US20070083240A1 (en) * 2003-05-08 2007-04-12 Peterson David K L Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
CA2527664A1 (en) * 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20050118246A1 (en) * 2003-10-31 2005-06-02 Wong Patrick S. Dosage forms and layered deposition processes for fabricating dosage forms
US7769461B2 (en) * 2003-12-19 2010-08-03 Boston Scientific Neuromodulation Corporation Skull-mounted electrical stimulation system and method for treating patients
US20080102119A1 (en) * 2006-11-01 2008-05-01 Medtronic, Inc. Osmotic pump apparatus and associated methods
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20050267555A1 (en) * 2004-05-28 2005-12-01 Marnfeldt Goran N Engagement tool for implantable medical devices
US20080027513A1 (en) * 2004-07-09 2008-01-31 Advanced Bionics Corporation Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
EP3417895A1 (en) 2004-07-28 2018-12-26 Medtronic Ardian Luxembourg S.à.r.l. Methods and devices for renal nerve blocking
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US9358393B1 (en) 2004-11-09 2016-06-07 Andres M. Lozano Stimulation methods and systems for treating an auditory dysfunction
US7483746B2 (en) * 2004-12-06 2009-01-27 Boston Scientific Neuromodulation Corp. Stimulation of the stomach in response to sensed parameters to treat obesity
US20070038264A1 (en) * 2004-12-21 2007-02-15 Jaax Kristen N Methods and systems for treating autism
US20060161217A1 (en) * 2004-12-21 2006-07-20 Jaax Kristen N Methods and systems for treating obesity
US9327069B2 (en) 2004-12-21 2016-05-03 Boston Scientific Neuromodulation Corporation Methods and systems for treating a medical condition by promoting neural remodeling within the brain
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US9352145B2 (en) * 2004-12-22 2016-05-31 Boston Scientific Neuromodulation Corporation Methods and systems for treating a psychotic disorder
US8515541B1 (en) 2004-12-22 2013-08-20 Boston Scientific Neuromodulation Corporation Methods and systems for treating post-stroke disorders
EP2351577A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
ATE401537T1 (en) * 2005-01-06 2008-08-15 Halton Oy VENTILATION REGISTERS AND VENTILATION SYSTEMS
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060185665A1 (en) * 2005-02-22 2006-08-24 Bachinski Thomas J Sauna fireplace
US20060194724A1 (en) * 2005-02-25 2006-08-31 Whitehurst Todd K Methods and systems for nerve regeneration
US7853321B2 (en) * 2005-03-14 2010-12-14 Boston Scientific Neuromodulation Corporation Stimulation of a stimulation site within the neck or head
US8423155B1 (en) 2005-03-14 2013-04-16 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US20060206165A1 (en) * 2005-03-14 2006-09-14 Jaax Kristen N Occipital nerve stimulation to treat headaches and other conditions
US7702385B2 (en) * 2005-11-16 2010-04-20 Boston Scientific Neuromodulation Corporation Electrode contact configurations for an implantable stimulator
US7848803B1 (en) 2005-03-14 2010-12-07 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
GB2442396B (en) * 2005-07-22 2011-05-11 Univ Utah Res Found Osmotically driven dispense pump and related components for use in high pressure applications
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US7684858B2 (en) * 2005-09-21 2010-03-23 Boston Scientific Neuromodulation Corporation Methods and systems for placing an implanted stimulator for stimulating tissue
EP1948246B1 (en) 2005-11-14 2017-05-03 Theragene Pharmaceuticals, Inc. Stem cell factor therapy for tissue injury
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7835803B1 (en) * 2006-01-17 2010-11-16 Boston Scientific Neuromodulation Corporation Lead assemblies with one or more switching networks
US8175710B2 (en) * 2006-03-14 2012-05-08 Boston Scientific Neuromodulation Corporation Stimulator system with electrode array and the method of making the same
US7777641B2 (en) * 2006-03-29 2010-08-17 Advanced Bionics, Llc Systems and methods of facilitating communication between a first and second device
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
US8504163B1 (en) 2006-06-30 2013-08-06 Boston Scientific Neuromodulation Corporation Cranially mounted stimulation systems and methods
US8401654B1 (en) 2006-06-30 2013-03-19 Boston Scientific Neuromodulation Corporation Methods and systems for treating one or more effects of deafferentation
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
US7445528B1 (en) 2006-09-29 2008-11-04 Boston Scientific Neuromodulation Corporation Connector assemblies
US7347746B1 (en) 2006-10-27 2008-03-25 Boston Scientific Neuromodulation Corporation Receptacle connector assembly
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
JP2012520884A (en) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー Methods and compositions for treating flaviviridae viral infections
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
FR2954936B1 (en) * 2010-01-06 2012-03-02 Oreal DEVICE FOR CONDITIONING AND APPLICATION COMPRISING AN APPLICATION MEMBER.
US9215921B2 (en) 2010-01-06 2015-12-22 L'oreal Packaging and applicator device including an applicator member
CN107007348B (en) 2010-10-25 2019-05-31 美敦力Af卢森堡有限责任公司 For the estimation of nerve modulation treatment and device, the system and method for feedback
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012175698A1 (en) 2011-06-23 2012-12-27 Université Libre de Bruxelles Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
EP2751291B1 (en) 2011-09-01 2018-08-15 University of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
CN104066432B (en) 2011-12-06 2017-06-13 小利兰·斯坦福大学董事会 Method and composition for treating viral disease
AU2013230781B2 (en) 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
RU2644933C2 (en) 2012-03-08 2018-02-14 Медтроник Аф Люксембург Сарл Biomarker samples selection as part of devices for neuromodulation and relevant systems and methods
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
CN105764491A (en) 2013-12-09 2016-07-13 度瑞公司 Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
JP2020506221A (en) 2017-01-04 2020-02-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Antibody fragments for the treatment of biofilm-related disorders
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CN110353973B (en) * 2019-07-03 2021-06-08 合肥职业技术学院 Medicine package composition release in hot spring water body
US20220275064A1 (en) 2019-07-08 2022-09-01 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3604417A (en) * 1970-03-31 1971-09-14 Wayne Henry Linkenheimer Osmotic fluid reservoir for osmotically activated long-term continuous injector device
US3760804A (en) * 1971-01-13 1973-09-25 Alza Corp Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
SE398976B (en) * 1971-01-13 1978-01-30 Alza Corp OSMOTIC DOSAGE DEVICE
CA949513A (en) * 1971-01-13 1974-06-18 Alza Corporation Osmotic dispenser
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser

Also Published As

Publication number Publication date
SE417158B (en) 1981-03-02
DK156243B (en) 1989-07-17
IL50468A0 (en) 1976-11-30
FR2347059A1 (en) 1977-11-04
JPS6039043B2 (en) 1985-09-04
US3987790A (en) 1976-10-26
DK156243C (en) 1989-12-04
JPS5244227A (en) 1977-04-07
DE2644267C2 (en) 1989-01-05
SE7610833L (en) 1977-04-02
GB1517879A (en) 1978-07-12
AU499196B2 (en) 1979-04-05
DK426776A (en) 1977-04-02
FR2347059B1 (en) 1979-09-28
DE2644267A1 (en) 1977-04-14
CH611800A5 (en) 1979-06-29
IT1068729B (en) 1985-03-21
AU1748876A (en) 1978-03-16
IL50468A (en) 1978-12-17

Similar Documents

Publication Publication Date Title
CA1053108A (en) Osmotically driven fluid dispenser
US4320758A (en) Osmotically driven fluid dispenser
US4976966A (en) Delayed release osmotically driven fluid dispenser
US4340054A (en) Dispenser for delivering fluids and solids
US4300558A (en) Self-driven fluid dispenser
CA1238543A (en) Osmotic capsule
US5017381A (en) Multi-unit pulsatile delivery system
KR100734187B1 (en) Valve for osmotic device
US5122128A (en) Orifice insert for a ruminal bolus
US4865845A (en) Release rate adjustment of osmotic or diffusional delivery devices
US4235236A (en) Device for dispensing drug by combined diffusional and osmotic operations
US3760984A (en) Osmotically powered agent dispensing device with filling means
US4693886A (en) Osmotic device with inert core
KR0176724B1 (en) Osmotic dosage system for liquid drug delivery
EP0040457A2 (en) Agent dispenser with microporous releasing diffusor
JP2005306885A (en) Osmotic delivery system with semipermeable plug
EP0089548A1 (en) Osmotic drug delivery system
KR20060112650A (en) Osmotic pump with self-retaining,fast-start membrane plug
DE3821424C2 (en) Multi-unit dispensing system
Srikonda et al. Osmotic controlled drug delivery systems
EP0325492A1 (en) Osmotic system for delivery of dilute solutions
CA1142831A (en) Osmotically driven fluid dispenser
US4946456A (en) Fluid imbibing pump activated by capillary action of a fabric or polymeric sleeve